• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Funxional Therapeutics Ltd - Product Pipeline Review - Q4 2010 Product Image

Funxional Therapeutics Ltd - Product Pipeline Review - Q4 2010

  • ID: 1446336
  • November 2010
  • 25 pages
  • GlobalData

Funxional Therapeutics Ltd – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Funxional Therapeutics Ltd - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Funxional Therapeutics Ltd - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Funxional Therapeutics Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Funxional Therapeutics Ltd Snapshot
Funxional Therapeutics Ltd Overview
Key Information
Key Facts
Funxional Therapeutics Ltd – Research and Development Overview
Key Therapeutic Areas
Funxional Therapeutics Ltd – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Funxional Therapeutics Ltd – Pipeline Products Glance
Funxional Therapeutics Ltd Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Funxional Therapeutics Ltd–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Funxional Therapeutics Ltd – Drug Profiles
FX125L
Product Description
Mechanism of Action
R&D Progress
FX125L
Product Description
Mechanism of Action
R&D Progress
FX141L
Product Description
Mechanism of Action
R&D Progress
FX87L
Product Description
Mechanism of Action
R&D Progress
Funxional Therapeutics Ltd – Pipeline Analysis
Funxional Therapeutics Ltd – Pipeline Products by Therapeutic Class
Funxional Therapeutics Ltd Pipeline Products By Target
Funxional Therapeutics Ltd – Pipeline Products by Route of Administration
Funxional Therapeutics Ltd – Pipeline Products by Molecule Type
Funxional Therapeutics Ltd - Dormant Projects
Funxional Therapeutics Ltd – Locations And Subsidiaries
Head Office
Recent Developments
May 26, 2010: Funxional Therapeutics Raises 10 Million Euros In A Private Series B Financing Round To Fund The Initial Phase II Clinical Studies Of FX125L In Inflammation
Jan 08, 2010: Funxional Therapeutics Announces Successful Completion Of Phase I Trial Of FX125L An Anti-Inflammatory Small Molecule
Jul 08, 2009: Funxional Successfully Completes Initial Clinical Trial Of FX125L, An Anti-Inflammatory Drug With A Novel Mechanism of Action
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS